CIDRAP – The new bivalent (two-strain) Moderna COVID-19 vaccine booster triggered stronger neutralizing antibody responses against the highly transmissible Omicron variant at 28 days than the previously authorized booster, with no safety concerns, according to the interim results of a phase 2/3 open-label, nonrandomized study published late last week in the New England Journal of Medicine.
Home
—
Global Center for Health Security
—
The Transmission
—
Updated COVID booster tied to strong Omicron immune response
Updated COVID booster tied to strong Omicron immune response
- Published Sep 22, 2022